


The listing of claims will replace all prior versions, and listings, of claims in the application:


Listing of Claims:

1. (Previously Presented) A compound of formula (I) or a salt, N-oxide, hydrate or solvate thereof:



wherein

R₁ is a group of formula (IA):



wherein in any compatible combination

Ar¹ is an optionally substituted aryl or heteroaryl radical,

Alk¹ and Alk² are optionally substituted divalent C₁-C₆ alkylene or C₂-C₆ alkenylene radicals,

p, r and s are independently 0 or 1,

Z is -O-, -S-, -(C=O)-, -(C=S)-, -SO₂-, -C(=O)O-, -C(=O)NR^A-, -C(=S)NR^A-, -SO₂NR^A-, -NR^AC(=O)-, -NR^ASO₂- or -NR^A- wherein R^A is hydrogen or C₁-C₆ alkyl, and

Q is hydrogen or an optionally substituted carbocyclic or heterocyclic radical;

R₂ is (i) a group of formula (IA) as defined in relation to R₁;

(ii) a carboxamide radical; or


(iii) a non aromatic carbocyclic or heterocyclic ring wherein a ring carbon is optionally substituted, and/or a ring nitrogen is optionally substituted by a group of formula -

$(\text{Alk}^1)_p-(\text{Z})_r-(\text{Alk}^2)_s-\text{Q}$ wherein Q, Alk^1 , Alk^2 , Z, p, r and s are as defined above in relation to group (IA); and

R_3 is hydrogen, or methyl, ethyl, n- or iso-propyl any of which being optionally substituted by hydroxy;


X is $-\text{OR}_4$ or $-\text{NR}_4\text{R}_5$ wherein R_4 and R_5 independently represent hydrogen or optionally substituted $\text{C}_1\text{-C}_6$ alkyl, or R_4 and R_5 taken together with the nitrogen to which they are attached form an optionally substituted nitrogen-containing ring having 5-8 ring atoms.

2. (Previously Presented) The compound as claimed in claim 1 wherein in the compound of formula (I), R_1 has formula (IB):



wherein R_6 is chloro, bromo, $\text{C}_1\text{-C}_6$ alkyl, or cyano.

3. (Previously Presented) The compound as claimed in claim 1 wherein in the compound of formula (I) R_1 has formula (IC):



wherein Alk^1 , Alk^2 , p, r, s, Z and Q are as defined in claim 1 in relation to formula (IA), and R

represents one or more optional substituents.

4. (Withdrawn) The compound as claimed in claim 2 wherein R is -OH in the 4- position of the phenyl ring and the $-(\text{Alk}^1)_p-(\text{Z})_r-(\text{Alk}^2)_s-\text{Q}$ substituent is in the 5- position of the phenyl ring.

5. (Withdrawn) The compound as claimed in claim 4 wherein r is 0, and Q is hydrogen or optionally substituted phenyl.

6. (Withdrawn) The compound as claimed in claim 5 wherein s is 0, p is 1 and Alk^1 is a nonsubstituted divalent $\text{C}_1\text{-C}_6$ alkylene or $\text{C}_2\text{-C}_6$ alkenylene radical.

7. (Withdrawn) The compound as claimed in claim 5 wherein Alk^1 is $-\text{CH}_2-$, $-\text{CH}_2\text{CH}_2-$, $-\text{CH}_2\text{CH}_2\text{CH}_2-$, or $-\text{CH}=\text{CH}-$.

8. (Withdrawn) The compound as claimed in claim 4 wherein p, r and s are each 0.

9. (Previously Presented) The compound as claimed in claim 1 wherein R_2 is phenyl, 2-, 3-, or 4-pyridyl, 2- or 3-furanyl, 2- or 3-thienyl, or thiazolyl, optionally substituted by one or more of methoxy, ethoxy, methylenedioxy, ethylenedioxy, fluoro, chloro, bromo, or trifluoromethyl.

10. (Previously Presented) The compound as claimed in claim 1 wherein R_2 is optionally substituted phenyl.

11 (Previously Presented) The compound as claimed in claim 1 wherein R_2 is phenyl substituted in the 4 position by (i) $\text{C}_1\text{-C}_6$ alkoxy such as methoxy or ethoxy, fluoro, chloro, bromo, morpholinomethyl, piperazino, N-methylpiperazino, or piperidino, (ii) optionally substituted $\text{C}_1\text{-C}_6$ alkyl, eg optionally substituted methyl, ethyl, n-propyl or iso-propyl (iii) optionally substituted morpholino $\text{C}_1\text{-C}_6$ alkyl-, thiomorpholino $\text{C}_1\text{-C}_6$ alkyl-, piperazino $\text{C}_1\text{-C}_6$ alkyl-, methyl piperazino $\text{C}_1\text{-C}_6$ alkyl-, or diethylamino (iv) $-\text{NH}_2$, $-\text{NHR}^A$, $-\text{NR}^A\text{R}^B$, $-\text{NHCOR}^A$, $-\text{NHCOOR}^A$, NR^BCOOR^A , $-\text{NHSO}_2\text{OR}^A$, $-\text{NR}^B\text{SO}_2\text{OR}^A$,

$-\text{NHCONH}_2$, $-\text{NR}^{\text{A}}\text{CONH}_2$, $\text{NHCONHR}^{\text{B}}$, $-\text{NR}^{\text{A}}\text{CONHR}^{\text{B}}$, $-\text{NHCONR}^{\text{A}}\text{R}^{\text{B}}$, or $-\text{NR}^{\text{A}}\text{CONR}^{\text{A}}\text{R}^{\text{B}}$
wherein R^{A} and R^{B} are independently a ($\text{C}_1\text{-C}_6$) alkyl group or (v) optionally substituted
piperadino, piperazino, morpholino or thiomorpholino.

12. (Withdrawn) The compound as claimed in claim 1 wherein R_2 is a carboxamide radical of
formula $-\text{CONR}^{\text{B}}(\text{Alk})_n\text{R}^{\text{A}}$ wherein

Alk is an optionally substituted divalent alkylene, alkenylene or alkynylene radical,

n is 0 or 1 ,

R^{B} is hydrogen or a $\text{C}_1\text{-C}_6$ alkyl or $\text{C}_2\text{-C}_6$ alkenyl group,

R^{A} is hydroxy or an optionally substituted carbocyclic or heterocyclic ring,

or R^{A} and R^{B} taken together with the nitrogen to which they are attached form an N-
heterocyclic ring which may optionally contain one or more additional hetero atoms
selected from O, S and N, and which may optionally be substituted on one or more ring C
or N atoms.

13. (Withdrawn) The compound as claimed claim 12 wherein

Alk is an optionally substituted $-\text{CH}_2-$, $-\text{CH}_2\text{CH}_2-$, $-\text{CH}_2\text{CH}_2\text{CH}_2-$, $-\text{CH}_2\text{CH}=\text{CH}-$, or
 $-\text{CH}_2\text{CCCH}_2-$ radical.

n is 0 or 1,

R^{B} is hydrogen, methyl, ethyl, n- or iso-propyl, or allyl,

R^{A} is hydroxy, hydroxy and/or chloro-substituted phenyl, 3,4 methylenedioxyphenyl,

pyridyl, furyl, thienyl, N-piperazinyl, or N-morpholinyl,

or R^A and R^B taken together with the nitrogen to which they are attached form a morpholino, piperidinyl, piperazinyl or N-phenylpiperazinyl ring.




14. (Withdrawn) The compound as claimed in claim 12 wherein n is 0, R^B is hydrogen and R^A is hydroxy or an optionally substituted carbocyclic or heterocyclic ring.
15. (Withdrawn) The compound as claimed in claim 1 wherein R₃ is hydrogen.
16. (Previously Presented) The compound as claimed in claim 1 wherein R₃ is other than hydrogen and the stereochemical configuration at the carbon centre to which it is attached is that of a D amino acid.
17. (Previously Presented) The compound as claimed in claim 1 wherein X is –OR₄ or –NHR₄ wherein R₄ is C₁-C₆ alkyl, optionally substituted by hydroxy, or a primary- secondary, tertiary- or cyclic-amino group
18. (Withdrawn) The compound as claimed in claim 1 wherein X is –NR₄R₅ wherein R₄ and R₅ taken together with the nitrogen to which they are attached form a morpholino, piperidinyl or piperazinyl ring, the latter being optionally substituted by C₁-C₆ alkyl on the second nitrogen.
19. (Withdrawn) A method of treatment of diseases or conditions mediated by excessive or inappropriate HSP90 activity in mammals which method comprises administering to the mammal an amount of a compound of formula (I) as defined in claim 1, or a salt, hydrate or solvate thereof, effective to inhibit said HSP90 activity.
20. (Withdrawn) The method as claimed claim 19 for immunosuppression or the treatment of cancer; viral disease, inflammatory diseases such as rheumatoid arthritis, asthma, multiple sclerosis, Type I diabetes, lupus, psoriasis and inflammatory bowel disease; cystic fibrosis






angiogenesis-related disease such as diabetic retinopathy, haemangiomas, and endometriosis; or for protection of normal cells against chemotherapy-induced toxicity; or diseases where failure to undergo apoptosis is an underlying factor; or protection from hypoxia-ischemic injury due to elevation of Hsp70 in the heart and brain; scrapie/CJD, Huntingdon's and Alzheimer's disease.





21. (Canceled)


22. (Canceled)

23. (Previously Presented) A compound









or a salt, solvate or hydrate thereof.

24. (Previously Presented) A pharmaceutical or veterinary composition comprising a compound as defined in claim 1, together with a pharmaceutically or veterinarily acceptable carrier.